COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control.
Marco CaminatiGabriella GuarnieriVeronica BataniElena ScarpieriAnita FinocchiaroFulvia Chieco-BianchiGianenrico SennaAndrea VianelloPublished in: Vaccines (2021)
Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.
Keyphrases
- sars cov
- end stage renal disease
- coronavirus disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- rheumatoid arthritis
- chronic obstructive pulmonary disease
- clinical trial
- randomized controlled trial
- open label
- patient reported outcomes
- combination therapy
- replacement therapy
- smoking cessation
- placebo controlled
- allergic rhinitis